FR2173988A1 - - Google Patents
Info
- Publication number
- FR2173988A1 FR2173988A1 FR7303843A FR7303843A FR2173988A1 FR 2173988 A1 FR2173988 A1 FR 2173988A1 FR 7303843 A FR7303843 A FR 7303843A FR 7303843 A FR7303843 A FR 7303843A FR 2173988 A1 FR2173988 A1 FR 2173988A1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22372372A | 1972-02-04 | 1972-02-04 | |
| US29145072A | 1972-09-22 | 1972-09-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2173988A1 true FR2173988A1 (ru) | 1973-10-12 |
| FR2173988B1 FR2173988B1 (ru) | 1976-10-22 |
Family
ID=26918072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7303843A Expired FR2173988B1 (ru) | 1972-02-04 | 1973-02-02 |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS5623994B2 (ru) |
| AU (1) | AU475978B2 (ru) |
| BE (1) | BE794964A (ru) |
| CA (1) | CA1009652A (ru) |
| DE (1) | DE2305575A1 (ru) |
| FR (1) | FR2173988B1 (ru) |
| GB (1) | GB1418822A (ru) |
| HK (1) | HK15581A (ru) |
| YU (2) | YU210773A (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2422649A1 (fr) * | 1978-04-10 | 1979-11-09 | Bristol Myers Co | Iminoquinazolines et leur utilisation a la preparation de la 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazoline-2(3h)-one |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE31617E (en) * | 1972-02-04 | 1984-06-26 | Bristol-Myers Company | Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones |
| NL7807507A (nl) * | 1977-07-25 | 1979-01-29 | Hoffmann La Roche | Tricyclische verbindingen. |
| CA1131631A (en) * | 1979-06-20 | 1982-09-14 | Madhukar S. Chodnekar | Quinazoline derivatives and pharmaceutical preparations |
| ZW16481A1 (en) * | 1980-08-15 | 1982-03-10 | Hoffmann La Roche | Novel imidazoquinazoline derivatives |
| JPS6028979A (ja) * | 1983-07-14 | 1985-02-14 | Dai Ichi Seiyaku Co Ltd | イミダゾキナゾリン類化合物 |
| CA2113115A1 (en) * | 1991-07-29 | 1993-02-18 | Vlad E. Gregor | Quinazoline derivatives as acetylcholinesterase inhibitors |
| HU219864B (hu) | 1994-08-09 | 2001-08-28 | Eisai Co., Ltd. | cGMP-PDE inhibitor kondenzált piridazinszármazékok és alkalmazásuk |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US8304420B2 (en) | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| GB0808968D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substitute quinazolines |
| GB0808947D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US9580471B2 (en) | 2011-03-01 | 2017-02-28 | Synergy Pharmaceuticals, Inc. | Process of preparing guanylate cyclase C agonists |
| US9545446B2 (en) | 2013-02-25 | 2017-01-17 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法 |
| JP6694385B2 (ja) | 2013-08-09 | 2020-05-13 | アーデリクス，インコーポレーテッド | リン酸塩輸送阻害のための化合物及び方法 |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
| CN117062819A (zh) * | 2021-03-23 | 2023-11-14 | 北京生命科学研究所 | 多环化合物及其用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2081375A1 (ru) * | 1969-12-18 | 1971-12-03 | Smith Kline French Lab |
-
0
- BE BE794964D patent/BE794964A/xx not_active IP Right Cessation
-
1973
- 1973-02-01 AU AU51668/73A patent/AU475978B2/en not_active Expired
- 1973-02-02 CA CA162,747A patent/CA1009652A/en not_active Expired
- 1973-02-02 FR FR7303843A patent/FR2173988B1/fr not_active Expired
- 1973-02-02 GB GB539073A patent/GB1418822A/en not_active Expired
- 1973-02-02 JP JP1303873A patent/JPS5623994B2/ja not_active Expired
- 1973-02-05 DE DE19732305575 patent/DE2305575A1/de active Granted
- 1973-08-03 YU YU02107/73A patent/YU210773A/xx unknown
-
1981
- 1981-04-23 HK HK155/81A patent/HK15581A/xx unknown
- 1981-06-15 YU YU01510/81A patent/YU151081A/xx unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2081375A1 (ru) * | 1969-12-18 | 1971-12-03 | Smith Kline French Lab |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2422649A1 (fr) * | 1978-04-10 | 1979-11-09 | Bristol Myers Co | Iminoquinazolines et leur utilisation a la preparation de la 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazoline-2(3h)-one |
Also Published As
| Publication number | Publication date |
|---|---|
| BE794964A (fr) | 1973-08-02 |
| CA1009652A (en) | 1977-05-03 |
| YU210773A (en) | 1983-02-28 |
| HK15581A (en) | 1981-05-01 |
| DE2305575A1 (de) | 1973-08-09 |
| JPS5623994B2 (ru) | 1981-06-03 |
| YU151081A (en) | 1983-12-31 |
| AU475978B2 (en) | 1976-09-09 |
| AU5166873A (en) | 1974-08-01 |
| JPS4886894A (ru) | 1973-11-15 |
| GB1418822A (en) | 1975-12-24 |
| DE2305575C2 (ru) | 1989-01-12 |
| FR2173988B1 (ru) | 1976-10-22 |